Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 593

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 593
---
 ) |     | $    |   (31,136 | ) |
| Denominator:                                           |     |                                  |           |   |     |      |           |   |     |                                 |           |   |     |      |           |   |
| Weighted average units outstanding - basic and diluted |     |                                  | 8,924,201 |   |     |      | 8,924,201 |   |     |                                 | 8,924,201 |   |     |      | 8,924,201 |   |
| Basic and diluted net loss per common unit             |     | $                                |     (0.00 | ) |     | $    |     (0.00 | ) |     | $                               |     (0.00 | ) |     | $    |     (0.00 | ) |

For the three and nine months ended September 30, 2024 and 2023, a total of 1,199,013 convertible preferred units were excluded from the calculation of diluted net loss per common unit as their effect on diluted net loss would have been anti-dilutive.

Note 6 - Commitments and Contingencies

Johns Hopkins University License Agreement

As discussed in Note 4, the Company has an exclusive worldwide license of a biomatrix technology developed at JHU, as amended. The Company is obligated to reimburse JHU for patent maintenance costs incurred for the licensed intellectual property. In addition, the Company is obligated to pay certain milestone fees upon commercial approval of any product developed from the licensed technology as well as payments upon reaching agreed upon sales milestones. The license agreement also includes minimum annual royalty payments commencing in 2029.

Note 7 – Contribution and Exchange Agreement

On August 7, 2022, the Company and each of its shareholders entered into a Contribution and Exchange Agreement (the “C&E Agreement”) with Longevity Biomedical, Inc. (“Longevity”). In connection with the signing of the C&E Agreement, Longevity entered into similar agreements with Cerevast Medical, Inc., and Novokera, LLC (collectively, along with Aegeria, the “Target Companies”). Upon the consummation of the transactions contemplated by the C&E Agreement and the agreements with the other Target Companies (collectively the “Acquisition Transactions”), the Target Companies will be acquired by Longevity.

| F-74 |

aegeria soft tissue llc

notes to the financial statements (UNAUDITED